Alembic Gets USFDA Nod for Generic Antidepressant Tablets
By Rediff Money Desk, New Delhi Jan 15, 2025 15:53
Alembic Pharmaceuticals has received USFDA approval for its generic version of Brexpiprazole tablets, used to treat major depressive disorder. The approval covers strengths ranging from 0.25 mg to 4 mg.

New Delhi, Jan 15 (PTI) Alembic Pharmaceuticals Ltd on Wednesday said it has received final approval from the US health regulator for its generic version of Brexpiprazole tablets used in treatment of major depressive disorder.
The approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) for Brexpiprazole tablets of strengths 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg, the company said in a statement.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti tablets of 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg, of Otsuka Pharmaceutical Company, Ltd, it added.
Brexpiprazole is an atypical antipsychotic used as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults, and also used in treatment of schizophrenia in adults and pediatric patients aged 13 years and older.
Citing IQVIA data, Alembic said Brexpiprazole tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg have an estimated market size of USD 2 billion for 12 months ended September 2024.
The approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) for Brexpiprazole tablets of strengths 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg, the company said in a statement.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti tablets of 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg, of Otsuka Pharmaceutical Company, Ltd, it added.
Brexpiprazole is an atypical antipsychotic used as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults, and also used in treatment of schizophrenia in adults and pediatric patients aged 13 years and older.
Citing IQVIA data, Alembic said Brexpiprazole tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg have an estimated market size of USD 2 billion for 12 months ended September 2024.
Source: PTI
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 9.47 (+ 2.05)
- 61048233
- Thinkink Picturez
- 0.45 ( 0.00)
- 22664084
- G G Engineering
- 1.22 ( -3.94)
- 18109205
- Srestha Finvest
- 0.69 ( -1.43)
- 12131937
- Hathway Cable & Data
- 14.75 ( -2.12)
- 11583833
MORE NEWS

Samsung India Employees Strike Over Union...
Employees at Samsung's Sriperumbudur plant in Tamil Nadu are on strike, demanding...
HC Robotics to Invest Rs 500 Cr in Telangana,...
Centillion Networks'' subsidiary HC Robotics will invest Rs 500 crore in Telangana,...

Ajax Engineering Raises Rs 379 Cr Ahead of IPO
Ajax Engineering, backed by Kedaara Capital, has secured Rs 379 crore from anchor...